Ruzasvir is under clinical development by Atea Pharmaceuticals and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Ruzasvir’s likelihood of approval (LoA) and phase transition for Hepatitis C took place on 09 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ruzasvir Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Ruzasvir is under development for the treatment of hepatitis C infection. The drug candidate is administered orally and targets NS5A antigen.
Atea Pharmaceuticals overview
Atea Pharmaceuticals (Atea) is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases including herpesvirus, hepatitis B, hepatitis C infections and HIV/AIDS. The company utilizes its purine nucleotide prodrug platform for the development of its products. Pipeline products of the company include AT527 for the treatment of COVID-19, AT-752 for dengue, AT-787 for Hepatitis C (HCV), AT-889 and AT-934 for the treatment of respiratory syncytial virus infection. Atea Pharmaceuticals is headquartered in Boston, Massachusetts, the US.
Quick View Ruzasvir LOA Data
|Highest Development Stage|